mtm Logo (WIPO, 08/05/2009)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark mtm was filed as Figurative mark on 08/05/2009 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Lines, bands #One line or one band #Curved lines or bands (except A 26.11.13)
| Trademark form | Figurative mark |
| File reference | 1016891 |
| Countries | 
|
| Base trademark |
No. 008131096,
March 2, 2009
|
| Application date | August 5, 2009 |
| Expiration date | August 5, 2019 |
Trademark owner
Im Neuenheimer Feld 583
69120 Heidelberg
DE
69120 Heidelberg
DE
Trademark representatives
Im Neuenheimer Feld 583
69120 Heidelberg
DE
goods and services
01
Chemicals used in industry and science, preparations,
reagents and kits for detection of cancerous conditions,
neoplastic conditions, inflammatory conditions, infectious
conditions, degenerative conditions, genetically aberrant or
diseased conditions, proliferatively aberrant or diseased
conditions, vascular disease conditions, premalignant
conditions, malignant conditions, cancer and inborn errors
for scientific or research use
05
Pharmaceutical and veterinary preparations, pharmaceutical
preparations for the treatment and prevention of neoplastic,
inflammatory, infectious, degenerative, genetic,
proliferative and vascular diseases and for the treatment of
premalignant and malignant cancerous conditions, cancer and
inborn errors; veterinary preparations for the treatment and
prevention of neoplastic, inflammatory, infectious,
degenerative, genetic and proliferative and vascular
diseases and for the treatment of premalignant and malignant
cancerous conditions, cancer and inborn errors in livestock,
cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats,
mice, rats, monkeys, apes and birds; medical diagnostic
reagents and kits for detection of cancer and neoplastic,
inflammatory, infectious, degenerative, genetic,
proliferative and vascular diseases and for the detection of
premalignant and malignant cancerous conditions, cancer and
inborn errors; medical diagnostic preparations including
in-vitro and in-vivo diagnostic testkits, diagnostic
immunocytochemical kits, diagnostic immunohistochemical
kits, diagnostic histology kits, diagnostic cytology kits,
diagnostic liquid-immuno-assay kits, diagnostic solid-phase
immuno-assay kits, diagnostic strip-tests, diagnostic
dip-stick-tests, point of care tests, diagnostic
lateral-flow assay kits, diagnostic flow-through assay kits,
diagnostic immunochromatographic kits
10
Diagnostic testing machines, including point-of-care testing
machines, diagnostic liquid-immuno-assay machines,
diagnostic immunocytochemical machines, diagnostic
immunohistochemical machines, diagnostic histology machines,
diagnostic cytology machines, diagnostic solid-phase immuno
assay machines, diagnostic ELISA testing machines,
diagnostic immuno-chromatographic machines all used to
analyze and/or provide diagnostic test results and used in
connection with early diagnosis, prognosis, grading,
monitoring, staging, predictive therapy guidance, patient
stratification or therapy guidance of premalignant and
malignant conditions, cancer, inborn errors and infectious
and genetic diseases associated with cancer, proliferative
diseases associated with neoplastics and dysplastic
conditions or vascular diseases as indicated above;
diagnostic equipment including containers, vessels, tubes,
multiwell-plates, columns, stripes, sticks, brushes,
syringes, needles, spatulas, swabs, clothes, tampons for use
in sampling, storing, transporting, preparing, enriching,
concentrating, testing, analysing and evaluating of
biological material and samples in connection with early
diagnosis, prognosis, grading, monitoring, staging,
predictive therapy guidance, patient stratification or
therapy guidance of premalignant and malignant conditions,
cancer, inborn errors and infectious, genetic, proliferative
or vascular diseases as indicated above; diagnostic nucleic
acid detection machines, diagnostic nucleic acid
amplification machines, diagnostic immuno-histology machines
and diagnostic immuno-cytology machines all used to analyze
and/or provide diagnostic test results and used in
connection with early diagnosis, prognosis, grading,
monitoring, staging, predictive therapy guidance, patient
stratification or therapy guidance of premalignant and
malignant conditions, cancer, inborn errors and infectious
and genetic diseases associated with cancer, proliferative
diseases associated with neoplastics and dysplastic
conditions or vascular diseases as indicated above;
diagnostic apparatuses and instruments including hand-held,
table-top and floor-standing centrifugal,
gravitational-separating, electrophoretic, chromatographic,
conductometric, potentiometric, spectrometric,
spectro-photometric, radiologic (electro)
magnetic-resonance, histological, microscopic or
in-vivo-imaging machines and apparatuses for use in
preparing, enriching, concentrating, testing, analysing and
evaluating of biological material and samples in connection
with early diagnosis, prognosis, grading, monitoring,
staging, predictive therapy guidance, patient stratification
or therapy guidance of premalignant and malignant
conditions, cancer, inborn errors and infectious, genetic,
proliferative or vascular diseases as indicated above for
clinical and medical laboratory use
42
Scientific and technological services and research and
design relating thereto, industrial analysis and research
services, design and development of computer hardware and
software, scientific analysis in the fields of chemistry,
biology and molecular biology, laboratory research in the
field of molecular biology; laboratory research in the
fields of pharmaceutics and food technology; providing
research in the fields of pharmaceutical, chemical and
diagnostic research; research and development of
pharmaceutical products and substances for others;
scientific research in the nature of scientific information
research services; chemical, biological, molecular biology
and pharmacogenomic analysis services
44
Medical services, veterinary services, medical diagnostic
services and provision of medical diagnostic information in
the field of detection of neoplastic, inflammatory,
infectious, degenerative, genetic, proliferative and
vascular diseases, premalignant and malignant cancerous
conditions, cancer and inborn errors; veterinary diagnostic
services and provision of veterinary diagnostic information
in the field of detection of neoplastic, inflammatory,
infectious, degenerative, genetic, proliferative and
vascular diseases, premalignant and malignant cancerous
conditions, cancer and inborn errors in livestock, cattle,
pigs, horses, deer, elk, moose, sheep, dogs, cats, mice,
rats, monkeys, apes and birds
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 15, 2020 | 2020/7 Gaz | Deletion | |
| October 19, 2017 | 2017/44 Gaz | US | RAW: Total Invalidation |
| February 13, 2012 | 2012/18 Gaz | KR | RAW: Rule 18ter(4) protected goods and services |
| June 28, 2011 | 2013/16 Gaz | RU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| March 8, 2011 | 2011/11 Gaz | KR | Rejection |
| December 17, 2010 | 2011/5 Gaz | TR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| November 11, 2010 | 2013/4 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| October 22, 2010 | 2013/4 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| October 1, 2010 | 2010/40 Gaz | KR | Rejection |
| September 22, 2010 | 2010/39 Gaz | RU | Rejection |
| September 21, 2010 | 2010/39 Gaz | CN | Rejection |
| July 16, 2010 | 2013/3 Gaz | AU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| May 13, 2010 | 2010/20 Gaz | JP | Rejection |
| December 30, 2009 | 2010/2 Gaz | TR | Rejection |
| December 16, 2009 | 2010/1 Gaz | AU | Rejection |
| December 1, 2009 | 2009/50 Gaz | US | Rejection |
| August 5, 2009 | EM | Registration |
ID: 141016891